文献速递脑血管病外科神经重症

入院脂蛋白相关磷脂酶A2是动脉瘤性蛛网膜下腔出血患者血管痉挛与预后的新型预测因子吗

Is Admission Lipoprotein-Associated Phospholipase A2 a Novel Predictor of Vasospasm and Outcome in Patients With Aneurysmal Subarachnoid Hemorrhage?
PubMed 文献 · Neurosurgery · 2020-01-01

该研究纳入103例出血后24小时内获取脂蛋白相关磷脂酶A2(Lp-PLA2)水平的动脉瘤性蛛网膜下腔出血(aSAH)患者,分析Lp-PLA2与血管痉挛及临床结局的关系。结果显示52例(50.49%)发生血管痉挛,Lp-PLA2对血管痉挛的预测效能显著高于改良Fisher分级(Z=2.499,P=.012)。6个月随访时44例(42.72%)预后不良、36例(34.95%)死亡,Lp-PLA2与WFNS分级均为显著预测因子,但Lp-PLA2预测预后不良和死亡的效能低于WFNS分级,差异无统计学意义(P=.366和0.115)。

要点

  • 血管痉挛患者Lp-PLA2水平显著高于无血管痉挛者(P<.001)。
  • Lp-PLA2预测血管痉挛的效能显著高于改良Fisher分级(Z=2.499,P=.012)。
  • 重症患者中Lp-PLA2>200 μg/L者6个月生存率显著更差(P=.001)。

核心结论

  • Lp-PLA2可能作为aSAH患者的新型预测因子。
  • 30例重症患者中,Lp-PLA2升高者6个月死亡风险高于未升高者。

研究设计与样本

  • 纳入103例出血后24小时内获取Lp-PLA2水平的aSAH患者,分析Lp-PLA2与血管痉挛及临床结局的关系。

主要发现

  • 52例(50.49%)发生血管痉挛,血管痉挛患者Lp-PLA2水平显著高于无血管痉挛者(P<.001)。
  • 改良Fisher分级(P=.014)和Lp-PLA2水平(P<.001)均为血管痉挛的显著预测因子。
  • Lp-PLA2预测血管痉挛的效能显著高于改良Fisher分级(Z=2.499,P=.012)。
  • 6个月随访时44例(42.72%)预后不良、36例(34.95%)死亡,WFNS分级和Lp-PLA2均为6个月预后不良和死亡的显著预测因子(均P<.001)。
  • Lp-PLA2对6个月预后不良和死亡的预测价值倾向于低于WFNS分级,但差异无统计学意义(P=.366和0.115)。

关键数值与推荐

  • Lp-PLA2预测血管痉挛的效能显著高于改良Fisher分级(Z=2.499,P=.012)。
  • Lp-PLA2预测6个月预后不良和死亡的效能与WFNS分级相比差异无统计学意义(P=.366和0.115)。
  • 重症患者中Lp-PLA2>200 μg/L者6个月生存率显著差于Lp-PLA2≤200 μg/L者(P=.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The relationships between lipoprotein-associated phospholipase A2 (Lp-PLA2) level, vasospasm, and clinical outcome of patients with aneurysmal subarachnoid hemorrhage (aSAH) are still unclear. OBJECTIVE: To identify the associations between admission Lp-PLA2 and vasospasm following subarachnoid hemorrhage and the clinical outcome of aSAH. METHODS: A total of 103 aSAH patients who had Lp-PLA2 level obtained within 24 h postbleeding were included. The relationships between Lp-PLA2 level, vasospasm, and clinical outcome were analyzed. RESULTS: Vasospasm was observed in 52 patients (50.49%). Patients with vasospasm had significantly higher Lp-PLA2 level than those without (P < .001). Both modified Fisher grade (P = .014) and Lp-PLA2 level (P < .001) were significant predictors associated with vasospasm. The Z test revealed that power of Lp-PLA2 was significantly higher than that of modified Fisher grade in predicting vasospasm (Z = 2.499, P = .012). At 6-mo follow-up, 44 patients (42.72%) had unfavorable outcome and 36 patients (34.95%) died. The World Federation of Neurosurgical Societies (WFNS) grade and Lp-PLA2 level were both significant predictors associated with 6-mo unfavorable outcome and mortality (all P < .001). The predictive values of Lp-PLA2 for unfavorable outcome and mortality at 6-mo tended to be lower than those of the WFNS grade, but the differences were not statistically significant (P = .366 and 0.115, respectively). Poor-grade patients having Lp-PLA2 > 200 μg/L had significantly worse 6-mo survival rate than poor-grade patients having Lp-PLA2 ≤ 200 μg/L (P = .001). CONCLUSION: The Lp-PLA2 might be useful as a novel predictor in aSAH patients. A total of 30 poor-grade patients; those with elevated Lp-PLA2 level have higher risk of 6-mo mortality compared to those without.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Ding CY, Cai HP, Ge HL, et al. Is Admission Lipoprotein-Associated Phospholipase A2 a Novel Predictor of Vasospasm and Outcome in Patients With Aneurysmal Subarachnoid Hemorrhage? Neurosurgery. 2020. PMID: 30850840. doi:10.1093/neuros/nyz041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。